Company Overview
- Headquarters
- 101 Montgomery St, San Francisco CA
- Website
- eidostx.com
- Phone
- (650) 391-****
- Employees
- 54
- Founded in
- 2016
- Industry
- BioTech/Drugs
- Stock Symbol
- NASDAQ:EID
- NAICS Code
- 54, 54171, 541, 5417
- SIC Code
- 873, 87
Financials & Stats
Revenue
$6B
Total Funding Amount
$64M
Who is Eidos Therapeutics
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company headquartered in San Francisco, California. Founded in 2016, the company employs 54 individuals. Eidos Therapeutics focuses on developing AG10, a targeted therapeutic designed to address transthyretin amyloidosis. Their primary customer base consists of patients suffering from this disease. Driven by a mission to improve and prolong the lives of patients with transthyretin amyloidosis, Eidos Therapeutics leverages expertise gained from years of research supported by Stanford’s SPARK program. For further information, please visit eidostx.com.
Company Leadership
Eidos Therapeutics Tech Stack
Companies Similar to Eidos Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to Eidos Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 6M | 22 | Houston, TX | 2003 | |
| 6M | 6 | 2014 | ||
| 6M | 3 | San Diego, CA | ||
| 6M | 4 | Mountain View, CA | 2017 | |
| 6M | 21 | Mountain View, CA |